Gold prices steady ahead of Fed decision; weekly weakness noted
BOSTON - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC), a clinical-stage biotherapeutics company, announced it will publish its Annual Report and Accounts for the year ended December 31, 2024, on April 30, 2025. The Boston-based company, known for developing new classes of medicine for serious diseases, will hold a conference call and presentation at 9:00 AM EDT / 2:00 PM BST to discuss the financial outcomes.
The upcoming webcast, accessible through the company’s investor relations website, will provide stakeholders and the public with insights into PureTech’s financial health and progress. The report is expected to detail the company’s performance and strategic developments over the past year.
PureTech’s research and development efforts have yielded a diverse pipeline of 29 therapeutics and therapeutic candidates, including three that have received U.S. Food and Drug Administration approval. The company’s approach involves both internal advancement and collaboration with its Founded Entities, with several programs in various stages of clinical development.
The company’s forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, highlight the anticipation of future developments and strategies. However, these projections are subject to risks, uncertainties, and other factors that could impact actual results. PureTech’s filings with the SEC, including its Annual Report on Form 20-F for the year ended December 31, 2023, outline these considerations in detail.
This announcement serves as a precursor to the full disclosure of financial results, allowing investors to prepare for a comprehensive review of the company’s financial and operational performance. The information provided is based on a press release statement from PureTech Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.